AN2 Therapeutics annual r&d spending
2021
2022
2023
2024
2025
AN2 Therapeutics R&D Spending Growth & History (ANTX)
AN2 Therapeutics's r&d spending was $24.8M for fiscal 2025.
View full AN2 Therapeutics company overviewAN2 Therapeutics annual r&d spending history
| Fiscal year | Period ended | R&D spending | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $24.8M | −$15.7M | −38.82% |
| 2024 | 2024-12-31 | $40.5M | −$14.4M | −26.21% |
| 2023 | 2023-12-31 | $54.9M | $26.4M | +92.46% |
| 2022 | 2022-12-31 | $28.5M | $12.4M | +76.47% |
| 2021 | 2021-12-31 | $16.2M | — | — |
AN2 Therapeutics quarterly r&d spending
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | R&D spending | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $6.0M | $2.8M | +88.09% |
| Q1 2026 | 2026-03-31 | $6.7M | −$947,000 | −12.31% |
| Q4 2025 | 2025-12-31 | $6.9M | $1.5M | +27.46% |
| Q3 2025 | 2025-09-30 | $7.0M | −$1.3M | −15.53% |
| Q2 2025 | 2025-06-30 | $3.2M | −$8.9M | −73.66% |
| Q1 2025 | 2025-03-31 | $7.7M | −$7.0M | −47.53% |
| Q4 2024 | 2024-12-31 | $5.4M | −$9.5M | −63.82% |
| Q3 2024 | 2024-09-30 | $8.3M | −$6.1M | −42.57% |
| Q2 2024 | 2024-06-30 | $12.1M | −$1.4M | −10.26% |
| Q1 2024 | 2024-03-31 | $14.7M | $2.7M | +22.28% |
| Q4 2023 | 2023-12-31 | $14.9M | $6.2M | +70.46% |
| Q3 2023 | 2023-09-30 | $14.4M | $7.0M | +94.25% |
| Q2 2023 | 2023-06-30 | $13.5M | $6.8M | +102.12% |
| Q1 2023 | 2023-03-31 | $12.0M | $6.4M | +112.76% |
| Q4 2022 | 2022-12-31 | $8.8M | $3.4M | +64.76% |
| Q3 2022 | 2022-09-30 | $7.4M | $2.1M | +38.97% |
| Q2 2022 | 2022-06-30 | $6.7M | $2.8M | +73.97% |
| Q1 2022 | 2022-03-31 | $5.6M | $4.0M | +241.60% |
| Q4 2021 | 2021-12-31 | $5.3M | — | — |
| Q3 2021 | 2021-09-30 | $5.3M | — | — |
| Q2 2021 | 2021-06-30 | $3.9M | — | — |
| Q1 2021 | 2021-03-31 | $1.6M | — | — |
AN2 Therapeutics r&d spending trends
Between the periods ended 2021-12-31 and 2025-12-31, AN2 Therapeutics's r&d spending increased from $16.2M to $24.8M, a change of $8.6M. The latest reported quarter, Q2 2026, shows $6.0M.
About the metric
What research and development spending means
Research and development (R&D) spending covers the costs of creating and improving products, services, software, technologies, and processes. Higher R&D spending may support future innovation, but the amount alone does not show whether those investments will generate returns.
Calculation and source
SEC-reported R&D expense
TickerStat standardizes research and development expense reported in company SEC filings, including the software-specific US-GAAP R&D concept when it is the filer’s primary R&D expense line. It is historical company-reported spending, not an estimate or forecast. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review AN2 Therapeutics source filings ↗